Provensis Company Profile
✉ Email this page to a colleague
What is the competitive landscape for PROVENSIS, and when can generic versions of PROVENSIS drugs launch?
PROVENSIS has one approved drug.
There are five US patents protecting PROVENSIS drugs.
There are eighty-seven patent family members on PROVENSIS drugs in thirty countries.
Summary for Provensis
| International Patents: | 87 |
| US Patents: | 5 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
Drugs and US Patents for Provensis
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Provensis | VARITHENA | polidocanol | SOLUTION;INTRAVENOUS | 205098-001 | Nov 25, 2013 | RX | Yes | Yes | 7,814,943 | See Plans and Pricing | Y | See Plans and Pricing | |||
| Provensis | VARITHENA | polidocanol | SOLUTION;INTRAVENOUS | 205098-001 | Nov 25, 2013 | RX | Yes | Yes | 9,480,652 | See Plans and Pricing | Y | See Plans and Pricing | |||
| Provensis | VARITHENA | polidocanol | SOLUTION;INTRAVENOUS | 205098-001 | Nov 25, 2013 | RX | Yes | Yes | 7,731,986 | See Plans and Pricing | Y | Y | See Plans and Pricing | ||
| Provensis | VARITHENA | polidocanol | SOLUTION;INTRAVENOUS | 205098-001 | Nov 25, 2013 | RX | Yes | Yes | 8,122,917 | See Plans and Pricing | Y | See Plans and Pricing | |||
| Provensis | VARITHENA | polidocanol | SOLUTION;INTRAVENOUS | 205098-002 | Dec 21, 2017 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Provensis
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Provensis | VARITHENA | polidocanol | SOLUTION;INTRAVENOUS | 205098-001 | Nov 25, 2013 | 8,734,833 | See Plans and Pricing |
| Provensis | VARITHENA | polidocanol | SOLUTION;INTRAVENOUS | 205098-001 | Nov 25, 2013 | 7,025,290 | See Plans and Pricing |
| Provensis | VARITHENA | polidocanol | SOLUTION;INTRAVENOUS | 205098-001 | Nov 25, 2013 | 8,323,677 | See Plans and Pricing |
| Provensis | VARITHENA | polidocanol | SOLUTION;INTRAVENOUS | 205098-001 | Nov 25, 2013 | 6,572,873 | See Plans and Pricing |
| Provensis | VARITHENA | polidocanol | SOLUTION;INTRAVENOUS | 205098-001 | Nov 25, 2013 | 7,842,282 | See Plans and Pricing |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for Provensis Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Hong Kong | 1094943 | See Plans and Pricing |
| Japan | 4731483 | See Plans and Pricing |
| Russian Federation | 2006121470 | See Plans and Pricing |
| Canada | 2546108 | See Plans and Pricing |
| Japan | 4988353 | See Plans and Pricing |
| >Country | >Patent Number | >Estimated Expiration |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
